ERBB2 and breast cancer: The postulated consensus that advanced age is associated with a more favorable tumor biology (more luminal tumors, fewer TN or HER2 tumors, lower proliferative rates) that allows less intensive treatment is contradicted by the observed poorer outcome of BC in older patients [8,26,31,32,33,34,35,36].